All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Magrolimab/Nivolumab Combos Drive Responses in Unresectable Advanced/Recurrent CRC

August 19th 2025

Magrolimab plus nivolumab and FOLFOX with bevacizumab or cetuximab yielded responses in advanced/recurrent colorectal cancer.

ATG-022 Earns Breakthrough Therapy Designation in China for Advanced Gastric/GEJ Adenocarcinoma

August 19th 2025

The NMPA has granted breakthrough therapy designation to ATG-022 for previously treated gastric and gastroesophageal junction adenocarcinoma.

Being Coachable Is Vital to Success

August 19th 2025

Jill Gilbert, MD discusses how being coachable and using feedback effectively can drive personal growth, team success, and continuous professional improvement.

Anlotinib Plus Epirubicin Elicits PFS Benefit in Advanced Soft Tissue Sarcoma

August 19th 2025

Anlotinib plus epirubicin conferred a significant PFS benefit vs epirubicin monotherapy in advanced soft tissue sarcoma.

Frontline Maintenance Avelumab Plus Sacituzumab Govitecan Extends PFS in Urothelial Cancer

August 19th 2025

JAVELIN Bladder Medley data show PFS improvement with avelumab plus sacituzumab govitecan as first-line maintenance vs avelumab alone in urothelial cancer.

Trispecific Antibody JNJ-5322 Shows Potential to Redefine Treatment in R/R Multiple Myeloma

August 18th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the rationale for evaluating the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Myeloma Experts Uncover Key Role for Neutrophils, Potential New Treatment Strategy

August 18th 2025

Research shows that blocking CXCR2 receptor reduced tumor growth and improved survival; clinical trial underway.

Ifinatamab Deruxtecan Earns FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer

August 18th 2025

The FDA has granted breakthrough therapy designation to ifinatamab deruxtecan for the treatment of patients with extensive-stage small cell lung cancer.

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC

August 18th 2025

Izalontamab brengitecan earned FDA breakthrough therapy designation for EGFR-mutated locally advanced or metastatic NSCLC.

Nirogacestat Wins EU Approval for Progressing Desmoid Tumors

August 18th 2025

The European Commission approved nirogacestat for the treatment of progressing desmoid tumors requiring systemic treatment.

Removal of REMS Requirements Improves Access to CAR T-Cell Therapy Across Hematologic Malignancies

August 18th 2025

Four expert hematologists discuss the FDA’s decision to remove REMS programs for CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies.

Adjuvant Atezolizumab Boosts DFS, OS in MIBC After Positive MRD Test

August 18th 2025

Adjuvant atezolizumab improved DFS and OS after a positive Signatera MRD test in muscle-invasive bladder cancer.

Thoracic Oncology Fellows Forum Is Highlighted by PRO Data and Tarlatamab in SCLC

August 18th 2025

Hematology/oncology fellows shared insights on notable presentations given during the OncLive Fellows Forum on Thoracic Oncology.

Phase 2/3 Trial Further Evaluates Ficerafusp Alfa With Pembrolizumab in HPV– Head and Neck Cancer

August 18th 2025

Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC, discusses ficerafusp alfa for the treatment of patients with HPV-negative head and neck cancer.

Five Under 5: Top Oncology Videos for the Week of 8/10

August 17th 2025

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

PLD Plus Ifosfamide Shows Promising Activity in Advanced Soft Tissue Sarcoma

August 17th 2025

PLD plus ifosfamide produced an ORR of 33% and a DCR of 83% in advanced soft tissue sarcoma, with manageable toxicity.

The OncFive: Top Oncology Articles for the Week of 8/10

August 16th 2025

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Working Smarter to Unpack the Challenges of a New Cancer Diagnosis

August 16th 2025

Ashish Saxena, MD, PhD, discusses how fellows can make the discussion of an initial cancer diagnosis as productive as possible for patients.

Neoadjuvant Olaparib Plus Carboplatin Reduces Residual Cancer Burden in BRCA1/2-Mutated, HRD+ TNBC

August 15th 2025

Neoadjuvant olaparib plus carboplatin led to a high RCB 0/1 rate in BRCA1/2-mutated, HRD+ TNBC.

New Treatment Eliminates Bladder Cancer in 82% of Patients

August 15th 2025

TAR-200 was found to be highly effective in treating select patients with bladder cancer whose tumors were previously unresponsive to therapy.